PVDF Capsule Tumor-Immune Model for Rapid Immunodrug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening immunoregulatory drugs are time-consuming and do not effectively target the immune system, failing to meet the diverse needs of clinical patients and delaying new drug development.
Innovation Solution
A novel animal model using polyvinylidene fluoride (PVDF) capsule tubes encapsulating a mixture of tumor and immune cells from fresh tumor tissues or body fluids, with a specific ratio of CD3+ T cells, allowing rapid screening of immunomodulatory drugs and identification of suitable biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional humanized mouse PDX experiment is used for modeling immunological treatments, then the model can provide comprehensive immune system evaluation, but the screening time is excessively long (2-5 months)
Solution Approach 1:
The patent segments the immune system evaluation into distinct functional modules by introducing multiple immunodeficient mouse strains (each lacking specific immune components) and assigning different immune cell types to specific evaluation tasks. This modular approach allows parallel evaluation of different immune functions simultaneously, reducing the overall screening time from 2-5 months to a much shorter period while maintaining comprehensive evaluation capability.
Solution Approach 2:
The patent creates a universal screening platform that can evaluate multiple immunomodulatory drugs across different immune system contexts using a standardized set of immunodeficient mouse models. This multi-functional system allows the same platform to assess various drug types (checkpoint inhibitors, cytokines, etc.) against different immune deficiencies, eliminating the need for separate lengthy studies for each drug type and enabling simultaneous multi-drug screening.
2Measurement precision
If classical PDX modeling is used, then the immune system can be evaluated in detail, but it fails to meet diversified needs for selecting multiple immune drugs
Solution Approach 1:
The patent changes the key parameter of immune system composition by utilizing different immunodeficient mouse strains with specific immune cell deficiencies (e.g., T-cell deficient, B-cell deficient, macrophage deficient models). This parameter variation allows the screening system to evaluate how different immunomodulatory drugs affect specific immune components, providing detailed mechanistic insights and enabling flexible selection of drugs based on diverse clinical needs and patient immune profiles.
Solution Approach 2:
The patent creates simplified copies of human immune system deficiencies using genetically engineered mouse models that replicate specific human immune conditions. These mouse models serve as surrogate systems that mirror human immune responses to immunomodulatory drugs, allowing comprehensive evaluation of drug effects on different immune pathways without requiring complex human clinical trials for each drug candidate.
3Measurement precision
If current drug sensitivity screening methods are used, then tumor cell response can be assessed, but immune system targeting and optimizing drug efficacy cannot be screened
Solution Approach 1:
The patent merges tumor cell culture with specific immunodeficient mouse models to create a hybrid in vivo screening system. Tumor cells are implanted into mice with defined immune deficiencies, allowing simultaneous assessment of tumor cell response and immune system interaction. This combined approach enables evaluation of both direct tumor cell effects and immune-mediated responses to immunomodulatory drugs, providing comprehensive data for drug selection and optimization.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides a model and method for rapid screening the efficacy of immunoregulatory drugs. The method comprises constructing an animal model containing PVDF capsule tubes, and further comprises analyzing the pharmacodynamic data for the animal model in vivo, phenotype identification by paired flow cytometry and multi-omics data. The PVDF capsule tubes have cells comprising tumor cells and immune cells in a single cell suspension; wherein the tumor cells and immune cells are derived from fresh tumor tissues or body fluids of clinical patients. The animal model constructed according to the present invention can be used for immune system targeting and drug efficacy regulation screening, and drug screening for multiple patients at the same time. It provides a rapid and effective method and model for clinical precision medicine and new drug development.